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1943Longer telomeres in PA-SMCs from iPAH patients
did not correlate with age (Figure 1B). Strikingly,
telomere lengths in iPAH positively and signiﬁcantly
(Spearman rank correlation r2 ¼ 0.818; p ¼ 0.00096)
correlated with pulmonary vascular resistance
values, suggesting a strong relationship between
disease severity and better telomere length mainte-
nance. This phenomenon seems to be exclusive to
PA-SMCs, because it was not found in matched
endothelial cells or peripheral blood cells (data not
shown).
Alterations in the proliferation capacity of the PA-
SMCs have been associated with pulmonary hyper-
tension. Recent studies have also highlighted the
similarities between iPAH and cancer, 2 diseases
that involve abnormal cell growth. Here, we extend
these similarities to aspects related to telomere
biology and show the correlation between telomere
maintenance and proliferation capacity of iPAH PA-
SMCs, as well as disease severity. This correlation,
probably related to an increase of telomerase activity
(4), seems to be exclusive to iPAH, because it was not
found in chronic obstructive pulmonary disease pul-
monary hypertension (5), suggesting that the mech-
anisms involved in the PA-SMC abnormal growth are
different. In conclusion, our work suggests that in
iPAH, PA-SMCs overcome the proliferation barriers
that operate in normal cells through a better main-
tenance of telomeres.Mohamed Izikki, PhD
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Necessary Before
Adenosine-Induced
Fractional Flow
Reserve Measurement?Caffeine antagonizes the pharmacological actions of
adenosine by blocking adenosine receptor activity (1).
A protocol for adenosine stress myocardial perfusion
imaging recommends that caffeine-containing prod-
ucts be withheld for 12 h before the test (2). However,
there has been no widely accepted consensus for the
need of caffeine abstention before fractional ﬂow
reserve (FFR) measurement. Conﬂicting results have
been reported in the literature concerning the effects
of caffeine on FFR measurement (3,4). Thus, we
designed this study to determine if caffeine absten-
tion is required before FFR measurement and if high-
dose intracoronary adenosine overcomes the caffeine
antagonism.
This prospective, single-center study enrolled
76 patients who underwent clinically indicated FFR
assessment. Of these patients, 19 patients in each
group were asked to refrain from caffeine-containing
products for 12, 24, and 48 h before the test and 19
patients were allowed to have caffeine. Exclusion
criteria included acute myocardial infarction, severe
arrhythmia, previous coronary artery bypass grafting,
any contraindications for adenosine or papaverine,
and the presence of pressure drift (>0.03) after pull-
back. Hyperemia was induced by central intravenous
adenosine at a dose of 140 mg/kg/min (ADN-IV), by
intracoronary adenosine at varying doses (60 mg
[ADN-IC60], 150 mg [ADN-IC150], 300 mg [ADN-IC300],
by 600 mg [ADN-IC600]), and by papaverine (10 to
12 mg in the right coronary artery or 15 to 20 mg in the
left coronary artery), as a reference standard. The
FIGURE 1 Comparisons of FFR Between Papaverine and Intravenous Adenosine
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.10
0.08
0.06
0.04
0.02
0.00
-0.02
-0.04
-0.06
AD
N-
IV
AD
N–
IV
 – 
Pa
pa
ve
rin
e
0.4 0.5 0.6 0.7 0.8 0.9 1.0
0 1 2 3 4 5 6 7 8
Caffeine Level (mg/l)
Papaverine
r = 0.48
p < 0.001
No abstention 12–h abstention
24–h abstention 48–h abstention
Caffeine
abstention n ADN–IV
Overestimation
(vs. papaverine) p value
No
12–h
24–h
48–h
19
19
19
19
0.804 ± 0.091
0.769 ± 0.096
0.754 ± 0.089
0.743 ± 0.141
0.045 ± 0.032
0.023 ± 0.020
0.015 ± 0.021
0.003 ± 0.022
< 0.001
< 0.001
< 0.01
0.61
A B
(A) Comparisons of fractional ﬂow reserve (FFR) between papaverine and intravenous adenosine. The dashed line indicates the line of identity.
(B) Scatterplots of caffeine level and difference in FFR values between intravenous adenosine and papaverine.
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1944next higher doses of intracoronary adenosine were
not administered in the event of a pause in the
heartbeat of >3 seconds.
The median caffeine levels were 1.424, 0.452,
0.240, and 0 mg/l (interquartile ranges: 0.876 to
4.764, 0.291 to 1.054, 0.060 to 0.303, and 0 to
0.002 mg/l) in the no caffeine, and 12-, 24-, and 48-h
caffeine abstention groups, respectively. The protocol
of ADN-IV was completed in all patients. Figure 1A
shows scatterplots of FFR between papaverine and
ADN-IV. Compared with papaverine, ADN-IV over-
estimated FFR in the no caffeine group (p < 0.001)
and in the 12-h (p < 0.001) and 24-h caffeine absten-
tion (p < 0.01) groups, whereas the difference in FFR
was not signiﬁcant in the 48-h abstention group
(p ¼ 0.61). The overestimation in FFR by ADN-IV was
correlated with caffeine levels (r ¼ 0.48; p < 0.001)
(Figure 1B). ADN-IV overestimated FFR in 91% (29 of
32) and 94% (16 of 17) of the patients who had caffeine
levels of >0.5 and >1.0 mg/l, respectively.
ADN-IC600 was feasible in 84% (51 of 61) of the
patients for the left coronary artery and in only 13%
(2 of 15) of the patients for the right coronary artery.
Incremental ADN-IC produced progressively lowered
FFR values in all the groups. However, even in-
creased doses of intracoronary adenosine up to
600 mg still overestimated FFR compared withpapaverine in the no caffeine group (p < 0.001) and
the 12-h (p < 0.01) and 24-h caffeine abstention
(p < 0.01) groups. In the 48-h caffeine abstention
group, the mean FFR value did not differ signiﬁcantly
between papaverine and ADN-IC600 (p ¼ 0.31),
whereas FFR was overestimated by ADN-IC60
(p < 0.01) and tended to be overestimated by
ADN-IC150 (p ¼ 0.07) and ADN-IC300 (p ¼ 0.05).
We found that the currently recommended central
ADN-IV overestimated FFR in the presence of caffeine
in a dose-dependent manner, and the increased doses
of ADN-IC up to 600 mg could not fully surmount the
antagonism. A review article suggested that a caffeine
level of <3 to 4 mg/l was acceptable for adenosine
stress myocardial perfusion imaging (5). However, the
remaining caffeine in the blood could be clinically
relevant for FFR measurement even after 24 h of
caffeine abstention.
The results of this study suggest prolonged caffeine
abstention (>24 h) would be safer to avoid incomplete
hyperemia. Otherwise, we would have to choose
alternative drugs that are unaffected by caffeine, such
as papaverine and nicorandil, when an FFR value ob-
tained with adenosine stays above 0.80.
In conclusion, caffeine abstention is necessary
before adenosine-induced FFR measurement, regard-
less of the administration route.
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2009;74:598–605.Going Over LEGACY With
a Pinch of SaltPathak et al. (1) reported that sustained weight loss
$10% in patients with a body mass index $27 kg/m2
was associated with a 6-fold reduction of atrial
ﬁbrillation (AF) recurrence during a 5-year follow-up,
compared to patients without weight loss. The non-
randomized design and statistical methods used raise
concerns about the extent to which the ﬁndings can
be considered valid.
The study was based on a post-hoc analysis of 355
patients, allocated to groups for comparison after
study completion according to the achieved weight
loss. We detected several potential sources of selec-
tion bias for these groups. Most importantly, patients
with the highest weight loss participated more
often in the offered dietician consulting, suggest-
ing generally better lifestyle management and drugtreatment compliance, which could also possibly
comprise a better control of other AF relevant com-
orbidities such as hypertension, obstructive sleep
apnea, or diabetes. Indeed, important information on
these comorbidities are missing, eliminating the
potential to assess their impact on AF: 1) classes and
doses of the antihypertensive drugs (rather than their
number per patient); 2) changes in apnea-hypopnea
index at follow-up; and 3) data on HbA1c at baseline
and follow-up (rather than fasting insulin levels that
do not inform about longer-term glycemic control).
Furthermore, patients with the highest weight loss
tended to be older than the control group. More de-
tails regarding AF treatment would also be helpful in
interpreting the results, since electrocardioversion,
number of ablations, and/or use of amiodarone at any
time could have inﬂuenced the maintenance of sinus
rhythm more robustly than sotalol or ﬂecainide use
alone. It is not clear whether the outcome was
adjusted for these variables.
Another form of bias includes attrition bias: the
information on the number and nature of dropouts is
missing. Although the authors aimed for a 5-year
follow-up, the average follow-up was 48 months for
unclear reasons. Dropouts due to death—especially in
older subjects (i.e., those with the highest weight
loss)—would have affected the outcome. In any study,
death can prevent detection of cause-speciﬁc nonfatal
endpoints. Hence an analysis combining AF recur-
rence and death is warranted as sensitivity analysis.
In our opinion, evaluating the real effect of weight
loss on AF would need a randomized controlled
study. Short of this, use of case-mix adjustments,
such as the propensity score matching, could provide
a better control for confounding.*Miroslava Valentova, MD
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